Stock

CVS Health to no longer sell decongestants with phenylephrine

U.S. pharmacy chain CVS Health said on Thursday it is pulling some of the most common decongestants with phenylephrine as the only active ingredient from its shelves and will no longer sell them.

The move comes after a panel of advisers to U.S. health regulators raised doubts over the efficacy of the ingredient.

Last month, the panel refused to back the effectiveness of oral over-the-counter medicines made with phenylephrine, adding that no more trials were required to prove otherwise.

CVS said “other oral cough and cold products will continue to be offered to meet consumer needs.”

Phenylephrine was substituted for pseudoephedrine in many non-prescription cold and allergy medicines after the latter was restricted amid reports of abuse.

Phenylephrine is a major component used in some of popular products like Benadryl, Sudafed, GSK’s Advil and Kenvue’s Tylenol.

This post appeared first on NBC NEWS

You May Also Like

Editor's Pick

ERP or Enterprise Resource Planning solutions help businesses of all sizes manage their daily business operations. First used in the 1990s, ERP systems have...

Investing

Democratic Gov. Janet Mills on Wednesday vetoed a bill aimed at prohibiting foreign influence in Maine elections, but voters will get the final say...

Latest News

There were several reasons offered in support of the congestion pricing plan that was supposed to go into effect in New York at the...

Latest News

House Speaker Mike Johnson (R-La.) on Wednesday appointed Reps. Scott Perry (R-Pa.) and Ronny Jackson (R-Tex.), two Trump loyalists who denied the results of...

Disclaimer: realinvestmentstar.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 realinvestmentstar.com